Two drugs are better than one. A short history of combined therapy of ovarian cancer.
Two drugs are better than one. A short history of combined therapy of ovarian cancer.
复制标题
DOI：
10.5114/wo.2014.43975
复制
发表时间：
2015
期刊：
影响因子：
--
通讯作者：
Marczak A
中科院分区：
文献类型：
--
作者：
Bukowska B;Gajek A;Marczak A
卵巢癌的综合治疗历史悠久。它已经应用了很多年。第一种通常与其他化疗药物联合使用的药物是顺铂。结果表明，它与烷基化剂和紫杉烷一起使用是有效的。另一种经常作为一线治疗基础的药物是阿霉素。由于副作用，传统化疗的使用往往受到限制。这就是为什么专门针对癌细胞的新药（例如单克隆抗体或表皮生长因子受体抑制剂）在与传统抗癌药物联合使用时提供了一个受欢迎的补充。联合使用的药物应该是协同的或至少是加性的。为了在合理的序列中评估药物之间相互作用的类型，使用了等密度分析。这种方法可以让人们评估这两种药物是否可以有效地结合，这可能会改善卵巢癌的治疗。
Combined therapy of ovarian cancer has a long history. It has been applied for many years. The first drug which was commonly combined with other chemotherapeutics was cisplatin. It turned out to be effective given together with alkylating agents as well as with taxanes. Another drug which is often the basis of first-line therapy is doxorubicin. The use of traditional chemotherapy is often limited due to side effects. This is why new drugs, targeted specifically at cancer cells (e.g. monoclonal antibodies or epidermal growth factor receptor inhibitors), offer a welcome addition when used in combination with conventional anticancer agents. Drugs applied in combination should be synergistic or at least additive. To evaluate the type of interaction between drugs in a plausible sequence, isobolographic analysis is used. This method allows one to assess whether the two agents could make an efficient combination, which might improve the therapy of ovarian cancer.